These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 37855278)

  • 1. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia.
    Zhang Y; Wu X; Sun X; Yang J; Liu C; Tang G; Lei X; Huang H; Peng J
    Mini Rev Med Chem; 2024; 24(6):642-663. PubMed ID: 37855278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening and Activity Evaluation of Novel BCR-ABL/T315I Tyrosine Kinase Inhibitors.
    Su J; Fu C; Wang S; Chen X; Wang R; Shi H; Li J; Wang X
    Curr Med Chem; 2024; 31(20):2872-2894. PubMed ID: 37211852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation.
    Wang S; Chen J; Hou R; Xiong Y; Shi H; Chen Z; Li J; Wang X
    Chem Biol Interact; 2024 Nov; 403():111248. PubMed ID: 39332790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
    Pan YL; Zeng SX; Hao RR; Liang MH; Shen ZR; Huang WH
    Eur J Med Chem; 2022 Aug; 238():114442. PubMed ID: 35551036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.
    Yang K; Fu K; Zhang H; Wang X; To KKW; Yang C; Wang F; Chen ZS; Fu L
    Mol Cancer; 2024 Sep; 23(1):209. PubMed ID: 39342174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
    Kumar H; Raj U; Gupta S; Varadwaj PK
    J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Hoy SM
    Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent Advance of Newly Therapy for Chronic Myeloid Leukemia with
    Lai HR; Wu QM; Yang YZ; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1579-1583. PubMed ID: 37846720
    [No Abstract]   [Full Text] [Related]  

  • 12. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 13. BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.
    Leonetti F; Stefanachi A; Nicolotti O; Catto M; Pisani L; Cellamare S; Carotti A
    Curr Med Chem; 2011; 18(19):2943-59. PubMed ID: 21651486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.
    Song T; Guo Y; Xue Z; Guo Z; Wang Z; Lin D; Zhang H; Pan H; Zhang X; Yin F; Wang H; Uwituze LB; Zhang Z
    Leukemia; 2021 Oct; 35(10):2862-2874. PubMed ID: 34007045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.